[Featured Stock] Russian Vaccine Investment EID Shows Early Session Strength, Up 17.2%

[Asia Economy Reporter Park So-yeon] Etron and EID, which invested in the Russian vaccine, are showing strong performance.

On the 4th, EID was trading at 327 won, up 48 won (17.2%) from the previous day as of 9:12 AM on the KOSPI market.

Recently, the international medical journal The Lancet published the Phase 3 clinical trial results of the Russian vaccine Sputnik V. The Lancet reported that the Russian vaccine's immune efficacy reached 92%, and in clinical trials involving more than 20,000 elderly people aged 60 and above, the immune efficacy was 91.8%, confirming its safety as well.

The Sputnik V vaccine is the only vaccine that can be distributed at room temperature (2°C to 8°C), and its price is affordable at under 20 dollars, raising the necessity for domestic supply of the Russian vaccine produced by Korea Corus, according to experts.

The Russian vaccine Sputnik V is being produced domestically by Korea Corus. Korea Corus, in which Etron and EID have invested 20 billion won, is producing 150 million doses of the Russian vaccine.

Russia began domestic inoculation with Sputnik V as early as December last year, and about 50 countries worldwide have pre-ordered the Russian vaccine. Among them, 12 countries including Algeria, Hungary, Iran, and Venezuela are scheduled to start Sputnik V vaccination.

Meanwhile, German Chancellor Merkel also hinted at the introduction of Sputnik V following the Phase 3 news, and the European Union (EU) approval process is currently underway.

This content was produced with the assistance of AI translation services.